North America Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Therapy (Radiotherapy, Surgery, Chemotherapy), By Cancer (Skin Cancer, Lymphoma), By Country (U.S., Canada),- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

North America Veterinary Oncology Market Size and Growth

The North America veterinary oncology market size was exhibited at USD 554.15 million in 2023 and is projected to hit around USD 1,556.54 million by 2033, growing at a CAGR of 10.88% during the forecast period 2024 to 2033.

North America Veterinary Oncology Market Size 2024 To 2033

North America Veterinary Oncology Market Key Takeaways:

  • Canine segment is dominated the market in 2023 with a share of 86.45%.
  • Based on therapy, surgery held the largest share of 37.0% in 2023.
  • Immunotherapy segment is estimated to grow at the fastest CAGR over the forecast period.
  • Based on cancer type, skin cancer segment held the largest share of 39.19% in 2023

Report Scope of North America Veterinary Oncology Market

 Report Coverage  Details
Market Size in 2024 USD 614.44 Million
Market Size by 2033 USD 1,556.54 Million
Growth Rate From 2024 to 2033 CAGR of 10.88%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Animal, Therapy, Cancer Type, Country
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Country scope U.S., Canada, Mexico
Key Companies Profiled Zoetis; Boehringer Ingelheim International GmbH.;Elanco; PetCure Oncology; Accuray Incorporated; Varian Medical Systems, Inc.; Morphogenesis, Inc.; Karyopharm Therapeutics, Inc.; Regeneus Ltd.; OHC (One Health Company)

Growing adoption of veterinary cancer medicines as treatment options and a rising incidence of cancer in the pet population are expected to drive the market over the coming years. The growing willingness of owners to pay for pet healthcare and government initiatives for veterinary cancer therapy are the primary market drivers. The rising number of veterinary clinical trials investigating the safety and effectiveness of various oncologic therapies in pets further contributes to market growth..

Moreover, increasing strategic initiatives for R&D of targeted therapies for cancer in companion animals is boosting market growth. For instance, in July 2023, Ardent Animal Health partnered with FidoCure to expand access to oncology innovation in veterinary medicine by leveraging the latter's genomic testing and precision medicine platform. Such expansion efforts and the need to provide comprehensive pet care are likely to drive the market over the forecast period.

Furthermore, increase in pet insurance adoption is driving the market by reducing financial barriers for pet owners. This growth in insurance coverage facilitates access to advanced cancer treatments and diagnostics, boosting demand for veterinary oncology services. According to the AVMA, pet owners are increasingly turning to pet insurance to manage the costs associated with their pets' healthcare. Between 2020 and 2022, there was a notable rise in spending on veterinary care for dogs, with the average annual expenditure for veterinary visits increasing from $224 in 2020 to $362 in 2022. California, New York, and Florida were identified as the states with the highest number of insured pets.

Additionally, the North American Pet Health Insurance Association (NAPHIA) stated that the pet insurance market in the U.S. reached approximately $3.2 billion in 2023. By the end of 2022, the number of insured pets in the U.S. had grown to around 4.8 million, marking a 22% increase compared to 2021.

Furthermore, the market is anticipated to grow due to increased corporate investments in canine cancer therapies. The companies are implementing strategies, such as licensing, R&D partnerships, and business growth, to improve their product portfolio in canine oncology. For instance, in June 2022, Boehringer Ingelheim signed a partnership agreement with CarthroniX to develop small molecule therapies in canine oncology. Thus, growing strategic initiatives by key players are expected to boost demand for the market.

North America Veterinary Oncology Market By Animal Insights

Canine segment is dominated the market in 2023 with a share of 86.45%. The rising incidence of canine cancer, rising investment in veterinary oncology research & development, and growing veterinary healthcare costs are expected to drive market growth. The demand for efficient and cutting-edge therapies for cancer is expected to grow along with the prevalence of canine cancer cases, fueling segment growth. For instance, as per the study published in February 2022 by Aging and Cancer, it is predicted that one out of every four dogs will be diagnosed with tumors in their lifetime. Cancer is the main cause of mortality for dogs older than middle age. Therefore, the need for treatments will continue to increase due to the growing incidence of cancer in dogs, driving sector growth.

Feline segment is expected to witness the fastest CAGR over the forecast period due to increase in feline population, prevalence of cancer and need for effective treatment. For instance, according to American Pet Products Association, in 2022, roughly 69 million households in the U.S. had cats, and younger generations, especially millennials, were more likely to own them. In addition, cat-related visits to the vet increased dramatically in the months following the COVID-19 outbreak. According to the World Small Animal Veterinary Association (WSAVA), one in five cats is susceptible to acquiring cancer throughout its lifespan. According to estimates, the market growth is driven by increasing numbers of pet cats, higher cancer rates, and more frequent veterinary visits.

North America Veterinary Oncology Market By Therapy Insights

Based on therapy, surgery held the largest share of 37.0% in 2023. Surgery is often most effective for tumors that can be completely removed without threatening crucial structures that have not yet spread to other parts of the body. In the case of malignant cancer, it is frequently the first step. If the tumor is low-grade and there are no signs of local or distant metastasis, malignant cancer surgery could help in achieving remission. If the surgery succeeds, there may be no need for additional therapy, and the cancer may never come back. The growing instances of surgeries performed on pets for their treatment and technological advancements in these procedures contribute to the market growth. However, surgical treatments can partially or completely remove tumors, but pets may have some pain & discomfort, which may limit the adoption of surgery by pet owners. This is expected to hinder the growth of this market segment over the forecast period. In addition, a growing number of research projects, including surgeries on pet populations, are being conducted, which is further boosting the market's expansion.

North America Veterinary Oncology Market Share, By Therapy, 2023 (%)

Immunotherapy segment is estimated to grow at the fastest CAGR over the forecast period. Immunotherapy is considered one of the most promising recent developments in tumor treatment, which strengthens the body's immune response against cancer. Several nonprofit organizations dedicated to animal health research are sponsoring studies to bring new treatment options to the market. For instance, the University of Minnesota received funding from the Morris Animal Foundation in January 2023 to study & develop novel immunotherapeutics for big-breed dogs suffering from osteosarcoma. Osteosarcoma is a fatal bone cancer. Thus, the companies working on immunotherapeutic R&D for veterinary cancer also contribute to the market's expansion. Moreover, the market is growing as a result of an increase in the number of veterinarians dedicated to conducting immunotherapy clinical trials and growing investment in canine oncology clinical trials. For instance, in November 2022, the NCI funded clinical trials for canine immunotherapy.

North America Veterinary Oncology Market By Cancer Type Insights

Based on cancer type, skin cancer segment held the largest share of 39.19% in 2023 due to the high prevalence of mast cell tumors, which are among the most common skin cancers in dogs. Mast cell tumors and other skin cancers are prevalent in pets, leading to increased demand for effective treatments and diagnostics. Additionally, increased awareness and advancements in targeted therapies and immunotherapy drive greater demand for effective treatments.

Others segment is expected to grow at the fastest CAGR over the forecast period. The growing incidence of adenocarcinoma is expected to drive the segment during the forecast period. According to data published by Veterinary Practice in September 2022, dogs with anal sac adenocarcinomas account for 17% of all perianal cancers. As they are slowly growing tumors, the prognosis is typically favorable. In addition, initiatives undertaken by public and private stakeholders are expected to contribute to segment growth. For instance, in May 2021, the World Small Animal Veterinary Association established the WSAVA Oncology Working Group (WOW) to develop global veterinary oncology practice guidelines. This would help educate owners about cancer in pets and enable veterinarians to improve treatment standards.

North America Veterinary Oncology Market By Country Insights

The increasing number of veterinary cancer care centers and availability of advanced treatment for pet cancer management in this region is one of the key factors driving market growth. For instance, In May 2024, ChemoTech’s Animal Care is launching its TSE cancer treatment technology in Canada, having secured a $37,000 initial order from an Ottawa clinic. The order is depending on successful electrical safety testing, which is expected to be completed in 3-6 weeks. This marks ChemoTech's first step toward commercialization in North America, with plans to expand their sales force as demand grows.

Moreover, growing strategic initiatives by key players to increase access to precision medicine treatments for pet oncology in North America are boosting demand for oncology care in the region. For instance, in July 2023, Ardent and FidoCure entered into a transformative partnership to increase access to oncology innovation in the animal health market. This collaboration uses each company's strengths to advance science, give more animals access to cutting-edge precision medicine, and promote innovation in North America veterinary oncology industry.

U.S. Veterinary Oncology Market Trends

The U.S. dominated the North America market with a share of 89.60% in 2023, attributed to the increasing focus on pet health, the presence of multiple key pet drug manufacturing companies, and the rapid adoption of innovative pet care options. Furthermore, the increasing government funding for pet oncology and the presence of well-established market players in veterinary oncology are expected to further drive the market.

Additionally, an increase in partnerships between key players, is driving the U.S. veterinary oncology therapy market. These partnerships enhance research, development, and distribution of innovative cancer treatments, improving access and outcomes for companion animals. For instance, In April 2023, Torigen Pharmaceuticals partnered with Veterinary Management Groups (VMG) to provide over 2,000 clinics access to its experimental autologous cancer immunotherapy for pets. This agreement aims to expand the availability of innovative cancer treatments for companion animals across the U.S., empowering veterinarians with advanced therapeutic options.

The veterinary oncology market in Canada is driven by the increasing incidence of cancer in pets, growing adoption of pet insurance, presence of regulatory authorities focused on improving animal care, and the presence of centers focused on animals. For instance, in July 2023, Thrive Pet Healthcare and Fidocure entered into a strategic partnership to enhance pet oncology treatment. Thrive Pet Healthcare has used Fidocure's precision medicine platform in more than 200 instances of canine cancer since the start of the partnership in 2022. These types of joint ventures in the country are fueling market growth with their work focused on providing comprehensive cancer care for both animals and humans.

Furthermore, growing coordination among veterinarian universities, educational hospitals, and private veterinary specialty practices around the country is leading to considerable cancer research being conducted in several prominent medical institutions. For instance, the Comparative Oncology Trials Consortium (COTC), governed by the Comparative Oncology Program of the NIH-NCI Center for Cancer Research, strives to develop and conduct clinical trials in cancer-stricken dogs to assess potential medicines. Such new initiatives that involve carrying out clinical trials for pet cancer investigation are contributing to market growth.

North America Veterinary Oncology Market Recent Developments

  • In April 2024, ELIAS Animal Health is expanding its Lenexa, Kansas facility to prepare for the commercial launch of ELIAS Cancer Immunotherapy (ECI), the USDA-approved adoptive cell therapy for canine osteosarcoma. The company is also seeking $10 million in Series A funding to support manufacturing and product development.

  • In October 2023, Merck Animal Health announced the availability of gilvetmab, a novel caninized monoclonal antibody for treating dogs with mast cell tumors and melanoma. This checkpoint inhibitor, recently conditionally licensed by the USDA, aims to enhance treatment options for veterinary oncologists across the U.S.

Some of the prominent players in the North America veterinary oncology market include:

  • Zoetis.
  • Boehringer Ingelheim International GmbH
  • Elanco
  • PetCure Oncology
  • Accuray Incorporated.
  • Varian Medical Systems, Inc.
  • Morphogenesis, Inc.
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • OHC (One Health Company)

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the North America veterinary oncology market

Animal Type

  • Canine
  • Feline
  • Equine

Therapy

  • Radiotherapy
    • Stereotactic Radiation Therapy
      • LINAC
      • Other Types
    • Conventional Radiation Therapy
  • Surgery
  • Chemotherapy
  • Immunotherapy
  • Other Therapies

Cancer Type

  • Skin Cancers
  • Lymphomas
  • Sarcomas
  • Others

Country

  • U.S.
  • Canada
  • Mexico

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope

1.1.1. Scope

1.1.2. Estimates And Forecast Timeline

1.2. Market Definitions

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased Database

1.4.2. Internal Database

1.5. Market Formulation & Validation

1.6. Model Details

1.6.1. Commodity flow analysis

1.6.2. Global Market: CAGR Calculation

1.7. Research Scope and Assumptions

1.7.1. List of Secondary Sources

1.7.2. List of Primary Sources

1.7.3. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.3. Competitive Insights

Chapter 3. North America Veterinary Oncology Market Variables, Trends, & Scope

3.1. Market Lineage Outlook

3.1.1. Parent Market Outlook

3.1.2. Related/Ancillary Market Outlook

3.2. Market Dynamics

3.2.1. Market Drivers Analysis

3.2.1.1. Increasing Prevalence Of Cancer In Pets

3.2.1.2. Increasing R&D In Pet Cancer Therapy

3.2.1.3. Growing Focus On Animal Safety

3.2.1.4. Growing Uptake Of Pet Insurance

3.2.1.5. Technological Advancements In Pet Cancer Treatment

3.2.1.6. Increase In Pet Population

3.2.2. Market Restraints Analysis

3.2.2.1. High cost of treatment

3.2.2.2. Adverse effects associated with therapies

3.2.2.3. Limited Clinical Evidence

3.2.3. Market Opportunity Analysis

3.2.4. Market Challenges Analysis

3.3. North America Veterinary Oncology Market Analysis Tools

3.3.1. Porter’s Five Forces Analysis

3.3.1.1. Bargaining power of the suppliers

3.3.1.2. Bargaining power of the buyers

3.3.1.3. Threats of substitution

3.3.1.4. Threats from new entrants

3.3.1.5. Competitive rivalry

3.3.2. PESTEL Analysis

3.3.2.1. Political landscape

3.3.2.2. Economic and Social Landscape

3.3.2.3. Technological landscape

3.3.2.4. Environmental Landscape

3.3.2.5. Legal landscape

3.4. COVID-19 Analysis

3.5. Estimated Pet Population, by key countries

Chapter 4. North America Veterinary Oncology Market: Animal Estimates & Trend Analysis

4.1. Segment Dashboard

4.2. North America Veterinary Oncology Market Movement Analysis

4.3. North America Veterinary Oncology Market Size & Trend Analysis, by Animal, 2021 to 2033 (USD Million)

4.4. Canine

4.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

4.5. Feline

4.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

4.6. Equine

4.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Veterinary Oncology Market: Therapy Estimates & Trend Analysis

5.1. Segment Dashboard

5.2. North America Veterinary Oncology Market Movement Analysis

5.3. North America Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2021 to 2033 (USD Million)

5.4. Radiotherapy

5.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.4.2. Stereotactic Radiation Therapy

5.4.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.4.2.2. LINAC

5.4.2.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.4.2.3. Other Type

5.4.2.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.4.3. Conventional Radiation Therapy

5.4.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.5. Surgery

5.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.6. Chemotherapy

5.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.7. Immunotherapy

5.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

5.8. Other Therapies

5.8.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

6.1. Segment Dashboard

6.2. North America Veterinary Oncology Market Movement Analysis

6.3. North America Veterinary Oncology Market Size & Trend Analysis, by Cancer type, 2021 to 2033 (USD Million)

6.4. Skin Cancer

6.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

6.5. Lymphomas

6.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

6.6. Sarcomas

6.6.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

6.7. Others

6.7.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Veterinary Oncology Market: Country Estimates & Trend Analysis

7.1. Country Dashboard

7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033

7.3. North America

7.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

7.3.2. U.S.

7.3.2.1. Key Country Dynamics

7.3.2.2. Competitive Insights

7.3.2.3. U.S. Veterinary Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.3.3. Canada

7.3.3.1. Key Country Dynamics

7.3.3.2. Competitive Insights

7.3.3.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

7.3.4. Mexico

7.3.4.1. Key Country Dynamics

7.3.4.2. Competitive Insights

7.3.4.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization

8.2. Company Market Position Analysis/ Heat Map Analysis

8.3. Estimated Company Market Share Analysis, 2024

8.4. Strategy Mapping

8.4.1. Mergers & Acquisitions

8.4.2. Partnerships & Collaborations

8.4.3. Others

8.5. Company Profiles

8.5.1. Zoetis

8.5.1.1. Participant’s Overview

8.5.1.2. Financial Performance

8.5.1.3. Product Benchmarking

8.5.1.4. Strategic Initiatives

8.5.2. Boehringer Ingelheim International GmbH.

8.5.2.1. Participant’s Overview

8.5.2.2. Financial Performance

8.5.2.3. Product Benchmarking

8.5.2.4. Strategic Initiatives

8.5.3. Elanco

8.5.3.1. Participant’s Overview

8.5.3.2. Financial Performance

8.5.3.3. Product Benchmarking

8.5.3.4. Strategic Initiatives

8.5.4. PetCure Oncology

8.5.4.1. Participant’s Overview

8.5.4.2. Financial Performance

8.5.4.3. Product Benchmarking

8.5.4.4. Strategic Initiatives

8.5.5. Accuray Incorporated

8.5.5.1. Participant’s Overview

8.5.5.2. Financial Performance

8.5.5.3. Product Benchmarking

8.5.5.4. Strategic Initiatives

8.5.6. Varian Medical Systems, Inc.

8.5.6.1. Participant’s Overview

8.5.6.2. Financial Performance

8.5.6.3. Product Benchmarking

8.5.6.4. Strategic Initiatives

8.5.7. Morphogenesis, Inc.

8.5.7.1. Participant’s Overview

8.5.7.2. Financial Performance

8.5.7.3. Product Benchmarking

8.5.7.4. Strategic Initiatives

8.5.8. Karyopharm Therapeutics, Inc.

8.5.8.1. Participant’s Overview

8.5.8.2. Financial Performance

8.5.8.3. Product Benchmarking

8.5.8.4. Strategic Initiatives

8.5.9. Regeneus Ltd.

8.5.9.1. Participant’s Overview

8.5.9.2. Financial Performance

8.5.9.3. Product Benchmarking

8.5.9.4. Strategic Initiatives

8.5.10. OHC (One Health Company)

8.5.10.1. Participant’s Overview

8.5.10.2. Financial Performance

8.5.10.3. Product Benchmarking

8.5.10.4. Strategic Initiatives

Chapter 9. Key Takeaways

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers